News Archive

July 2020

• 
  Story Jul 30, 2020 Discovery

  Collaborating to explore new gene regulation therapies

  Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

• Press Release Jul 29, 2020

  Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

  Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial…
• Featured News Jul 29, 2020

  Choice with Responsibility: Reimagining how we work

• Press Release Jul 27, 2020

  Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

  Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150…
• Press Release Jul 27, 2020

  New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept

  A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept…
• 
  Story Jul 24, 2020 Discovery

  Breaking a vicious cycle of inflammation

  Novartis researchers aim to quash inflammation to treat chronic disease.

• Press Release Jul 24, 2020

  Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease

  If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-…
• Featured News Jul 24, 2020

  Expanding CAR-T manufacturing in Europe to serve more patients

  European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

• 
  Story Jul 23, 2020 Discovery

  Helping clinical trial patients during a lockdown

  Yan Zhao talks about how her team in China responded to an emerging public health crisis.

• Press Release Jul 23, 2020

  Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

  Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1…
• Key Release Jul 21, 2020

  Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.

  En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du…
• Key Release Jul 21, 2020

  Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

  Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%  (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):…